^
Association details:
| Biomarker: | MCL1 expression |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | alvocidib (DSP-2033) (CDK4 inhibitor, CDK6 inhibitor, CDK9 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
1959 - CDK9 inhibition combined with hypomethylating agents target MCL-1 dependency in MDS and AML
Published date:
03/14/2021
Excerpt:
These pre-clinical and clinical data suggest that an alvocidib/HMA combination may constitute a viable therapeutic regimen whose rationale focuses on hypertargeting of NOXA/MCL-1. Taken together, these studies indicate that the combination of alvocidib and HMAs drives AML/ MDS cells toward MCL-1 dependent apoptosis.
